Aakar Medical IPO 2025: Full Review & Investment Guide

India’s IPO market continues to heat up in 2025 with yet another notable public issue — Aakar Medical Technologies Limited. The company’s IPO opened for bidding on 20th June 2025 and will remain live until 24th June 2025, drawing attention for its consistent financial growth, diversified medical aesthetic portfolio, and low entry price point.

This article offers an in-depth 2000-word analysis of Aakar Medical Technologies IPO, including its financial health, business profile, grey market premium (GMP), valuation metrics, and expert commentary to help investors make a well-informed decision ahead of the 27th June 2025 listing.

IPO Overview: Aakar Medical Technologies

Aakar Medical Technologies Limited, incorporated in 2013, specializes in the import and distribution of aesthetic medical equipment and cosmetic devices. The company has carved a niche among dermatologists, cosmetologists, plastic surgeons, and aesthetic physicians by offering both indigenously manufactured and internationally sourced products.

Key IPO Details:

Investors can participate via a minimum application of 1 lot, costing ₹1,15,200, making it moderately accessible compared to other IPOs in 2025.

Share Reservation Breakdown

In accordance with SEBI guidelines, Aakar Medical Technologies IPO has reserved shares for multiple investor classes:

This ensures healthy participation across retail and institutional categories, promoting fair and equitable distribution.

About the Company: Aakar Medical Technologies Limited

Aakar Medical is an Indian aesthetic medical devices company offering dermatology and cosmetology solutions. With strategic sourcing from South Korea, Spain, Italy, and Austria, and the promotion of homegrown brands, the firm has rapidly scaled in a highly specialized niche.

Key Offerings:

• Laser-based devices

• Skin treatment machines

• Cosmetic consumables

• Injection-based therapy kits

• Anti-aging equipment

With India’s aesthetic and cosmetic dermatology market expected to grow at 18–20% CAGR, Aakar Medical is well-positioned to tap into rising consumer demand driven by urbanization, disposable income, and beauty awareness.

Financial Performance: Strong Growth Momentum

Aakar Medical has shown steady growth in revenue and profitability over the last three years.

Financials Snapshot:

Key Observations:

• Revenue CAGR (FY23–25): ~37.6%

• PAT CAGR (FY23–25): ~71.6%

• Zero PAT volatility suggests improving margins

• Debt has risen, but so has net worth — indicating capital investment in growth rather than distress

The PAT doubling in FY25, just before IPO, may raise concerns over sustainability — a typical caution signal in IPO narratives.

Technical Indicators and Valuation Metrics

Investors and analysts use financial ratios to determine valuation comfort and listing gain potential. Here’s how Aakar Medical stacks up:

Pre-Issue Key Ratios:

Post-Issue Estimates:

The moderate PE suggests the IPO is not exorbitantly priced. But post-issue valuation jumps could affect investor expectations for early listing gains.

Grey Market Premium (GMP) Trends

As of 19th June 2025, Aakar Medical IPO shows zero GMP, meaning no expected premium at listing.

While neutral GMP might concern short-term investors, it also suggests the IPO is being evaluated based on fundamentals, not hype.

Promoter Holdings

The company is closely held, with over 91% promoter ownership before the IPO.

High promoter holding suggests strong founder confidence, though post-issue dilution will reduce their stake.

Objective of the Issue

Aakar Medical Technologies intends to utilize the ₹27.00 crore IPO proceeds for:

1. Working capital requirements

2. General corporate purposes

No part of the proceeds is being used for debt repayment, though rising debt over three years calls for scrutiny of future capital deployment.

Subscription & Allotment

As of now, subscription data is yet to be updated, but live tracking will be available through:

• NSE India portal

• Registrar portal: Bigshare Services

How to Apply:

Applications can be placed via any stock broker or platforms like Univest, Zerodha, Groww, Upstox, etc.

Expert Review: Should You Invest?

“AMTL has shown strong revenue and PAT growth. However, a sharp profit spike in FY25 — just ahead of IPO — raises concerns. While the business model is promising, long-term investors should approach with moderate exposure.”
– Dilip Davda, Chittorgarh

✅ Pros:

• High revenue and PAT growth

• Niche and fast-growing aesthetic healthcare market

• Moderate pricing and low PE ratio

• Promoter skin in the game

❌ Cons:

• Sudden jump in profitability before IPO

• Low GMP signals lack of short-term interest

• Modest market capitalization (₹100+ cr)

• High debt increase over the last 2 years

Allotment Status: How to Check?

After IPO closure, allotment status will be available by 25th June 2025 via:

Method 1: NSE Portal

1. Visit https://www.nseindia.com

2. Go to IPO Allotment

3. Enter PAN or application number

Method 2: Bigshare Services Portal

1. Visit https://www.bigshareonline.com

2. Navigate to “IPO Allotment”

3. Enter application details

4. View status

Final Verdict: Is Aakar Medical Technologies IPO Worth It?

Aakar Medical Technologies IPO is an attractive proposition for long-term investors looking to bet on India’s booming aesthetic healthcare sector. The company has shown solid financial growth, a focused niche, and reasonable pricing.

However, short-term listing gains appear unlikely due to a flat GMP and aggressive FY25 growth, which could normalize in subsequent quarters.

Investment Advice:

• Retail investors can consider applying for long-term growth potential

• HNIs should apply only if comfortable with moderate-risk profiles

• Avoid if seeking quick listing gains

ALSO READ: Safe Enterprises IPO Opens: Detailed 2025 Investment Guide